Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. In our lead programs, we are developing multiple product candidates that target the insulin-like growth factor-1 receptor (IGF-1R) to treat patients who suffer from thyroid eye disease (TED), a debilitating auto-immune disease.
Learn more about Viridian and our programs in our corporate presentation.
Recent Press Releases
- Viridian Therapeutics Appoints Kristian Humer as Chief Financial Officer and Chief Business Officer
- Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee
- Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)